TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24850369

Group type: EXPERIMENTAL
Intervention: Baseline amotivation
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Neurocognition
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Motivational deficits
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Neurocognitive deficits
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Heinrichs-Carpenter Quality of Life Scale
Number of subjects: 754
Study: 24852804

Group type: EXPERIMENTAL
Intervention: Coronary Orbital Atherectomy System (OAS)
Number of subjects: 443
Study: 24852920

Group type: EXPERIMENTAL
Intervention: SR Fampridine 10 mg BID for 4 weeks
Number of subjects: 108
Study: 24853169

Group type: EXPERIMENTAL
Intervention: Benznidazole 5-8 mg/kg/day BID for 60 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Benznidazole plasma concentrations in children
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Benznidazole treatment in children under 7 years
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison of clearance rates
Number of subjects: 40
Study: 24854384

Group type: COMPARATOR
Intervention: Middle-aged type 2 diabetes (MA-DM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Aged Type 2 diabetes (A-DM)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Middle-aged normal glucose tolerance (MA-NGT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aged normal glucose tolerance (A-NGT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diabetes (DM)
Number of subjects: 50
Study: 24854484

Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 129

Group type: COMPARATOR
Intervention: hCG
Number of subjects: 129
Study: 24855165

Group type: EXPERIMENTAL
Intervention: Optimized insulin injection technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard insulin injection technique
Number of subjects: 0
Study: 24855212

Group type: EXPERIMENTAL
Intervention: Carfilzomib, cyclophosphamide, and dexamethasone (CCyd)
Number of subjects: 58
Study: 24857248

Group type: EXPERIMENTAL
Intervention: Home discharge
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Inpatient floor admission
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 304

Group type: COMPARATOR
Intervention: ICU admission vs floor admission
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Antiplatelet/anticoagulation therapy
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Skull fracture
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Lower GCS
Number of subjects: 304

Group type: COMPARATOR
Intervention: Level of care
Number of subjects: 304
Study: 24857280

Group type: EXPERIMENTAL
Intervention: Isotonic saline nasal irrigation (twice daily for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intranasal corticosteroid alone
Number of subjects: 40
Study: 24857345

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day, escalated by 50 mg every 2 weeks to a maximum of 300 mg/day)
Number of subjects: 49
Study: 24858016

Group type: EXPERIMENTAL
Intervention: CIDP patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 18
Study: 24858447

Group type: EXPERIMENTAL
Intervention: Caregivers with mild to severe depressive symptoms (PHQ-9 scores ≥5, n=116)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Caregivers with no depressive symptoms (PHQ-9 scores <5, n=126)
Number of subjects: 242
Study: 24859362

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1776
Study: 24859363

Group type: EXPERIMENTAL
Intervention: Carfilzomib, rituximab, and dexamethasone (CaRD)
Number of subjects: 20
Study: 24859366

Group type: EXPERIMENTAL
Intervention: SL-401 at 12.5 μg/kg intravenously over 15 minutes daily for up to 5 doses
Number of subjects: 11
Study: 24859907

Group type: EXPERIMENTAL
Intervention: Panobacumab (three doses of 1.2 mg/kg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no panobacumab)
Number of subjects: 31
Study: 24860459

Group type: EXPERIMENTAL
Intervention: Robot-assisted walking sessions for 45 min, 5 times a week for 4 weeks
Number of subjects: 5
Study: 24860718

Group type: EXPERIMENTAL
Intervention: TAC + bevacizumab (n=92)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: TCH + bevacizumab (n=34)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: TAC + bevacizumab
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: TCH + bevacizumab
Number of subjects: 127
Study: 24861484

Group type: EXPERIMENTAL
Intervention: Serum YKL-40 levels at 32 weeks of gestation
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Uterine artery pulsatility index at 32 weeks
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Serum YKL-40 levels
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Uterine artery notching
Number of subjects: 1214
Study: 24861649

Group type: EXPERIMENTAL
Intervention: ESS505 (new iteration of the ESSURE insert)
Number of subjects: 35

Group type: COMPARATOR
Intervention: ESS305 (previous version of the device)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ESS505
Number of subjects: 35

Group type: COMPARATOR
Intervention: ESS305
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ESS505 and ESS305
Number of subjects: 35
Study: 24862257

Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 1884
Study: 24862645

Group type: EXPERIMENTAL
Intervention: Recent lacunar infarcts
Number of subjects: 3005

Group type: EXPERIMENTAL
Intervention: Moderate-severe white matter hyperintensities
Number of subjects: 3005

Group type: EXPERIMENTAL
Intervention: Infarct location
Number of subjects: 3005
Study: 24862830

Group type: EXPERIMENTAL
Intervention: Metformin; specific dosage and duration not mentioned
Number of subjects: 0
Study: 24864123

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 36
Study: 24865607

Group type: EXPERIMENTAL
Intervention: Klinefelter syndrome patients with skewed X-inactivation
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Klinefelter syndrome patients
Number of subjects: 73
Study: 24867540

Group type: EXPERIMENTAL
Intervention: Neoadjuvant short-course proton-based radiation with capecitabine (5 daily doses of 5 GyE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neoadjuvant short-course proton-based radiation with capecitabine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Biomarker studies
Number of subjects: 50
Study: 24867717

Group type: EXPERIMENTAL
Intervention: Natrelle round silicone implants (augmentation)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Natrelle round silicone implants (revision-augmentation)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Natrelle round silicone implants (reconstruction)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Submuscular placement of implants (augmentation)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Overall implants (magnetic resonance imaging cohort)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Augmentation subjects
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Revision-augmentation subjects
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Reconstruction subjects
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Overall breast satisfaction
Number of subjects: 715
Study: 24868099

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg per day until disease progression or intolerable adverse events
Number of subjects: 42
Study: 24869942

Group type: EXPERIMENTAL
Intervention: HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) after ex vivo elimination of αβ(+) T cells and CD19(+) B cells
Number of subjects: 23
Study: 24870935

Group type: EXPERIMENTAL
Intervention: IL-6 (doubling)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: D-dimer (doubling)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: hsCRP (1-unit increase)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: IL-6 and D-dimer score (1-unit increase)
Number of subjects: 288
Study: 24871871

Group type: EXPERIMENTAL
Intervention: AnaConDa (ACD) with 0.8% sevoflurane
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AnaConDa (ACD) without sevoflurane
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional heat and moisture exchanger (HME)
Number of subjects: 12
Study: 24872229

Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin 2 (1.5 million IU/d for 5 days, followed by three 5-day courses of 3 million IU/d at weeks 3, 6, and 9)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin 2
Number of subjects: 5
Study: 24872402

Group type: EXPERIMENTAL
Intervention: Tirasemtiv 375 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Tirasemtiv 750 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Tirasemtiv 500 mg (after dose adjustment)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 24872728

Group type: EXPERIMENTAL
Intervention: Early follow-up by telephone consultations (4 and 14 days post-discharge) in addition to conventional treatment
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional treatment following discharge from hospital
Number of subjects: 116
Study: 24874071

Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in A/J mice
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in smokers with and without COPD
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Acrolein exposure
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Chronic inflammation established
Number of subjects: 4
Study: 24875132

Group type: EXPERIMENTAL
Intervention: AZD8931 monotherapy (40/60/80 mg bid for 21 days)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: AZD8931 40 mg bid plus paclitaxel 90 mg/m² (days 1, 8, 15 of 28-day cycle)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: AZD8931 monotherapy and combination therapy
Number of subjects: 17
Study: 24875672

Group type: EXPERIMENTAL
Intervention: Moderate-high isoflavone consumption (>1.48 mg/day, N = 65)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: High isoflavone consumption
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Soy consumption
Number of subjects: 215
Study: 24876081

Group type: EXPERIMENTAL
Intervention: Better collateral grade (American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Worse collaterals
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Better collaterals
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Better collateral grade
Number of subjects: 119
Study: 24876082

Group type: EXPERIMENTAL
Intervention: Trevo thrombectomy
Number of subjects: 228

Group type: COMPARATOR
Intervention: Merci thrombectomy
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: National Institutes of Health Stroke Scale score
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Symptom onset to endovascular treatment time
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Symptom onset to reperfusion time beyond 5 hours
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Symptomatic intracranial hemorrhage
Number of subjects: 228
Study: 24876243

Group type: EXPERIMENTAL
Intervention: Acute Stroke Program of Interventions Addressing Racial and Ethnic Disparities (ASPIRE) intervention
Number of subjects: 10256

Group type: EXPERIMENTAL
Intervention: Community interventions (e.g., preparedness bracelets and stroke warning magnets)
Number of subjects: 10256

Group type: EXPERIMENTAL
Intervention: Evaluation of emergency medical services and hospital processes for acute stroke care
Number of subjects: 10256
Study: 24876244

Group type: EXPERIMENTAL
Intervention: Solitaire FR thrombectomy
Number of subjects: 202

Group type: COMPARATOR
Intervention: Intravenous tissue-type plasminogen activator
Number of subjects: 202

Group type: COMPARATOR
Intervention: Magnetic resonance-based imaging at baseline
Number of subjects: 202

Group type: COMPARATOR
Intervention: Extracranial carotid disease
Number of subjects: 202
Study: 24876969

Group type: EXPERIMENTAL
Intervention: Adult Myopathy Assessment Tool (AMAT)
Number of subjects: 56
Study: 24878054

Group type: EXPERIMENTAL
Intervention: Congenital adrenal hyperplasia (CAH) treatment
Number of subjects: 199

Group type: COMPARATOR
Intervention: Non-salt-wasting classic CAH
Number of subjects: 199

Group type: COMPARATOR
Intervention: Moderately affected genotype group B women
Number of subjects: 199

Group type: COMPARATOR
Intervention: Late diagnosis of classic CAH (after 1 year)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Glucocorticoid only treatment in women
Number of subjects: 199
Study: 24878127

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 2209

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 2209

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 2209

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 2209

Group type: EXPERIMENTAL
Intervention: PCI in diabetics
Number of subjects: 2209

Group type: COMPARATOR
Intervention: CABG in diabetics
Number of subjects: 2209

Group type: EXPERIMENTAL
Intervention: PCI in patients with multivessel disease
Number of subjects: 2209

Group type: COMPARATOR
Intervention: CABG in patients with multivessel disease
Number of subjects: 2209

Group type: EXPERIMENTAL
Intervention: PCI in ST elevation myocardial infarction
Number of subjects: 2209

Group type: COMPARATOR
Intervention: CABG in ST elevation myocardial infarction
Number of subjects: 2209
Study: 24878825

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the dorsal pallidum (globus pallidus, GP)
Number of subjects: 2
Study: 24879333

Group type: EXPERIMENTAL
Intervention: Alisertib ECT (50 mg BID for 7 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alisertib ECT (doses ≥ 40 mg BID)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alisertib ECT
Number of subjects: 24
Study: 24879786

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous 23-valent polysaccharide vaccine (PPSV23)
Number of subjects: 0
Study: 24879788

Group type: EXPERIMENTAL
Intervention: 454-GSS
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 454-GSS < 3
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sanger-GSS < 3
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Previous antiretrovirals received
Number of subjects: 132
Study: 24879813

Group type: EXPERIMENTAL
Intervention: Anticoagulation stopped in patients with persistently negative D-dimer (528 patients)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Patients who resumed anticoagulation (373 patients)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Patients who refused anticoagulation (109 patients)
Number of subjects: 1010
Study: 24879827

Group type: EXPERIMENTAL
Intervention: Veo
Number of subjects: 27

Group type: COMPARATOR
Intervention: FBP
Number of subjects: 27
Study: 24879829

Group type: EXPERIMENTAL
Intervention: Brief-H-Neg
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Brief-H-Pos
Number of subjects: 5000
Study: 24879844

Group type: EXPERIMENTAL
Intervention: hsTnT
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Combination of hsTnT and NT-proBNP
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: hsTnT addition
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: NT-proBNP addition
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Both markers together
Number of subjects: 439
Study: 24880136

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus salivarius PS2) administered for 21 days
Number of subjects: 0
Study: 24880739

Group type: EXPERIMENTAL
Intervention: Change in body mass index (BMI)
Number of subjects: 2593

Group type: EXPERIMENTAL
Intervention: Change in waist circumference (WC)
Number of subjects: 2593

Group type: EXPERIMENTAL
Intervention: Change in waist circumference-height ratio (WHtR)
Number of subjects: 2593
Study: 24881994

Group type: EXPERIMENTAL
Intervention: Hypertension (blood pressure ≥140/90 mm Hg or those receiving blood pressure-lowering drugs)
Number of subjects: 1250000

Group type: COMPARATOR
Intervention: Normal blood pressure
Number of subjects: 1250000

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure of 90-114 mm Hg and diastolic blood pressure of 60-74 mm Hg
Number of subjects: 1250000

Group type: EXPERIMENTAL
Intervention: High systolic blood pressure
Number of subjects: 1250000

Group type: EXPERIMENTAL
Intervention: Raised diastolic blood pressure
Number of subjects: 1250000

Group type: EXPERIMENTAL
Intervention: Pulse pressure
Number of subjects: 1250000

Group type: EXPERIMENTAL
Intervention: Stable and unstable angina
Number of subjects: 1250000

Group type: EXPERIMENTAL
Intervention: Heart failure and stable angina
Number of subjects: 1250000
Study: 24882673

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160mg orally daily
Number of subjects: 60
Study: 24883065

Group type: EXPERIMENTAL
Intervention: Baseline serum levels of FGF21 in girls
Number of subjects: 179

Group type: COMPARATOR
Intervention: Baseline serum levels of FGF21 in boys
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Correlation of baseline FGF21 levels with triglycerides
Number of subjects: 179

Group type: COMPARATOR
Intervention: Correlation of baseline FGF21 levels with BMI, DXA-derived fat percentage, LDL, HDL, non-HDL cholesterol, leptin, and adiponectin
Number of subjects: 179

Group type: COMPARATOR
Intervention: Correlation of baseline FGF21 levels with dynamic changes in glucose and insulin levels during OGTT
Number of subjects: 179
Study: 24883207

Group type: EXPERIMENTAL
Intervention: First trimester elevated homocysteine levels
Number of subjects: 100
Study: 24883378

Group type: EXPERIMENTAL
Intervention: Recurrence Rate (RR) analysis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Spectral analysis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bispectral analysis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Approximate entropy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonlinear energy operator (NLEO)
Number of subjects: 14
Study: 24884405

Group type: EXPERIMENTAL
Intervention: Kidney transplantation (KT)
Number of subjects: 1000
Study: 24884512

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (5 g/d of fish oil supplement containing 1.9-2.2 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid) for 6 weeks
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation
Number of subjects: 210
Study: 24884681

Group type: EXPERIMENTAL
Intervention: Neurological examination, Glascow Coma Scale, and Modified Mini-Mental State Examination
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Initial clinical presentation with coma
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Age and gender factors
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Presence of cranial nerve deficits at onset
Number of subjects: 55
Study: 24884694

Group type: EXPERIMENTAL
Intervention: Intensified treatment of cardiovascular risk factors over 3 months, maintained for 2 years.
Number of subjects: 97
Study: 24884708

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease management and monitoring
Number of subjects: 2450
Study: 24884782

Group type: EXPERIMENTAL
Intervention: Modified-release hydrocortisone
Number of subjects: 801

Group type: COMPARATOR
Intervention: Conventional glucocorticoid replacement therapy
Number of subjects: 801
Study: 24884784

Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB) program delivered for 48 weeks with a 24-week post-intervention follow-up.
Number of subjects: 0
Study: 24884976

Group type: EXPERIMENTAL
Intervention: Seva (E-Health integrated communication technology delivered via mobile phones)
Number of subjects: 0
Study: 24885112

Group type: EXPERIMENTAL
Intervention: Tumor metabolic progression index (TMPI) measured by serial FDG PET-CT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline tumor FDG uptake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI-based apparent diffusion coefficient (ADC) and variation of vADC using voxel-based diffusion maps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating tumor cells (CTCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genomic and epigenetic factors
Number of subjects: 0
Study: 24885137

Group type: EXPERIMENTAL
Intervention: Obese men (BMI ≥30 kg/m2)
Number of subjects: 4131

Group type: EXPERIMENTAL
Intervention: Overweight women (BMI 25-29.9 kg/m2)
Number of subjects: 4131

Group type: COMPARATOR
Intervention: Normal weight subjects (BMI 18.5-24.9 kg/m2)
Number of subjects: 4131
Study: 24885258

Group type: EXPERIMENTAL
Intervention: HER2-targeted therapies
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Healthcare resource utilization
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Clinical data abstraction
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Tumor tissue and blood sample collection
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Demographic and clinicopathological data
Number of subjects: 1000
Study: 24885461

Group type: EXPERIMENTAL
Intervention: Non-left sleeping position
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Control group (ongoing singleton pregnancies)
Number of subjects: 1245
Study: 24885544

Group type: EXPERIMENTAL
Intervention: Quality improvement multi-faceted program including organizational, environmental, educational, human, and security approaches.
Number of subjects: 45260
Study: 24885621

Group type: EXPERIMENTAL
Intervention: Basic training (1-day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Enhanced training (3-day)
Number of subjects: 96
Study: 24885689

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) liquid cord cleansing
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Community and health workers' practices regarding delivery and cord care
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Use of sterilized equipment during delivery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Early initiation of breastfeeding and feeding colostrum
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Keeping babies warm after birth and delaying the first bath
Number of subjects: 80